Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.316
Buy
RSI(14)
61.269
Neutral
STOCH(KDJ)(9,3,3)
67.570
Sell
ATR(14)
0.790
High Vlolatility
CCI(14)
44.041
Neutral
Williams %R
31.333
Buy
TRIX(12,20)
2.901
Sell
StochRSI(14)
0.000
Oversold
CAMP4 Therapeutics Corp
CAMP6.000USD
-0.380-5.96%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
281.28MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of CAMP4 Therapeutics Corp
Currency: USD Updated: 2025-12-22Key Insights
CAMP4 Therapeutics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 77/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CAMP4 Therapeutics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
8.500
Target Price
+132.88%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CAMP4 Therapeutics Corp Highlights
StrengthsRisks
CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. It is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Growing
The company is in a growing phase, with the latest annual income totaling USD 652.00K.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 652.00K.
Undervalued
The company’s latest PE is -2.44, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 313.51K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-22The current financial score of CAMP4 Therapeutics Corp is 7.52, ranking 109/404 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
9.15
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.76
Operational Efficiency
3.13
Growth Potential
10.00
Shareholder Returns
7.53
CAMP4 Therapeutics Corp's Company Valuation
Currency: USD Updated: 2025-12-22The current valuation score of CAMP4 Therapeutics Corp is 7.81, ranking 83/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.44, which is -78.82% below the recent high of -0.52 and -82.26% above the recent low of -4.45.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 77/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-22The current earnings forecast score of CAMP4 Therapeutics Corp is 8.67, ranking 72/404 in the Biotechnology & Medical Research industry. The average price target for CAMP4 Therapeutics Corp is 7.50, with a high of 12.00 and a low of 7.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
8.500
Target Price
+132.88%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
CAMP4 Therapeutics Corp
CAMP
6
CRISPR Therapeutics AG
CRSP
30
argenx SE
ARGX
25
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-22The current price momentum score of CAMP4 Therapeutics Corp is 9.17, ranking 48/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 7.90 and the support level at 3.50, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
6.546
Sell
MA10
6.230
Sell
MA20
4.826
Buy
MA50
4.193
Buy
MA100
3.203
Buy
MA200
2.795
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-22The current institutional shareholding score of CAMP4 Therapeutics Corp is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 24.28%, representing a quarter-over-quarter decrease of 56.99%. The largest institutional shareholder is The Vanguard, holding a total of 313.51K shares, representing 0.60% of shares outstanding, with 47.90% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2025-12-22The current risk assessment score of CAMP4 Therapeutics Corp is 1.44, ranking 330/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+79.36%
240-Day Volatility
+146.36%
Return
Best Daily Return
60 days
+26.03%
120 days
+40.20%
5 years
--
Worst Daily Return
60 days
-17.38%
120 days
-18.46%
5 years
--
Sharpe Ratio
60 days
+2.92
120 days
+2.99
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+79.36%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
+0.39
3 years
--
5 years
--
Skewness
240 days
+1.33
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+146.36%
5 years
--
Standardised True Range
240 days
+6.65%
5 years
--
Downside Risk-Adjusted Return
120 days
+605.45%
240 days
+605.45%
Maximum Daily Upside Volatility
60 days
+99.33%
Maximum Daily Downside Volatility
60 days
+73.88%
Liquidity
Average Turnover Rate
60 days
+0.53%
120 days
+1.05%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
CAMP4 Therapeutics Corp
CAMP
7.06 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.47 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.43 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.40 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of CAMP4 Therapeutics Corp?
The TradingKey Stock Score provides a comprehensive assessment of CAMP4 Therapeutics Corp based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of CAMP4 Therapeutics Corp’s performance and outlook.
How do we generate the financial health score of CAMP4 Therapeutics Corp?
To generate the financial health score of CAMP4 Therapeutics Corp, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects CAMP4 Therapeutics Corp's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of CAMP4 Therapeutics Corp.
How do we generate the company valuation score of CAMP4 Therapeutics Corp?
To generate the company valuation score of CAMP4 Therapeutics Corp, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare CAMP4 Therapeutics Corp’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of CAMP4 Therapeutics Corp’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of CAMP4 Therapeutics Corp.
How do we generate the earnings forecast score of CAMP4 Therapeutics Corp?
To calculate the earnings forecast score of CAMP4 Therapeutics Corp, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on CAMP4 Therapeutics Corp’s future.
How do we generate the price momentum score of CAMP4 Therapeutics Corp?
When generating the price momentum score for CAMP4 Therapeutics Corp, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of CAMP4 Therapeutics Corp’s prices. A higher score indicates a more stable short-term price trend for CAMP4 Therapeutics Corp.
How do we generate the institutional confidence score of CAMP4 Therapeutics Corp?
To generate the institutional confidence score of CAMP4 Therapeutics Corp, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about CAMP4 Therapeutics Corp’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of CAMP4 Therapeutics Corp.
How do we generate the risk management score of CAMP4 Therapeutics Corp?
To assess the risk management score of CAMP4 Therapeutics Corp, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of CAMP4 Therapeutics Corp’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of CAMP4 Therapeutics Corp.
